Phase I Evaluation of Intravenous Ascorbic Acid in Combination with Gemcitabine and Erlotinib in Patients with Metastatic Pancreatic Cancer

Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer

(2011) Michael Graham Espey et al.   FREE RADICAL BIOLOGY AND MEDICINE

Phase II study of a fixed dose-rate infusion of gemcitabine associated with erlotinib in advanced pancreatic cancer

(2010) J. Feliu et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Vitamin C: Intravenous Use by Complementary and Alternative Medicine Practitioners and Adverse Effects

(2010) Sebastian J. Padayatty et al.   PLoS One

CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials

(2010) Kenneth F Schulz et al.   Trials

Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer

(2009) David Cunningham et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I clinical trial of i.v. ascorbic acid in advanced malignancy

(2008) L. J. Hoffer et al.   ANNALS OF ONCOLOGY

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice

(2008) Q. Chen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA